Compass Therapeutics (CMPX) Common Equity (2018 - 2026)

Compass Therapeutics' Common Equity history runs 9 years deep, the most recent figure standing at $186.5 million for Q1 2026.

• In Q1 2026, Common Equity rose 69.09% year-over-year to $186.5 million; the TTM figure through Mar 2026 stood at $186.5 million (up 69.09% YoY), while the FY2025 annual figure was $196.8 million, up 57.14% from the prior year.
• Common Equity came in at $186.5 million for Q1 2026 at Compass Therapeutics, down from $196.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $209.6 million in Q3 2025 to a low of $93.2 million in Q2 2025.
• A 5-year average of $151.4 million and a median of $148.5 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 386.09% in 2022 and plunged 36.21% in 2025, its largest moves.
• Compass Therapeutics' Common Equity stood at $181.6 million in 2022, then declined by 18.22% to $148.5 million in 2023, then retreated by 15.69% to $125.2 million in 2024, then soared by 57.14% to $196.8 million in 2025, then retreated by 5.24% to $186.5 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $186.5 million, $196.8 million, and $209.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison